Payment overview · 2025
General Payments
$343.98
16 reported records · 7 companies
Healthcare provider profile · identity verified
Jane Hope Reed, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · POWDERLY, KY · NPI 1881037323
Verified facts
What the public records show
CMS Open Payments records show Jane Hope Reed, APRN received $343.98 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.73 | 26.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.11 | 18.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.04 | 18.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.73 | 13.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.21 | 12.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.90 | 4.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.26 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $343.98 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.11 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.28 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.57 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.57 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 262 | 32 |
| Lisinopril | Lisinopril | 253 | 59 |
| Omeprazole | Omeprazole | 210 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 37 |
| Furosemide | Furosemide | 194 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 39 |
| Metformin Hcl | Metformin Hcl | 179 | 41 |
| Gabapentin | Gabapentin | 175 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 47 |
| Fenofibrate | Fenofibrate Nanocrystallized | 143 | 31 |
| Alprazolam | Alprazolam | 128 | 17 |
| Losartan Potassium | Losartan Potassium | 119 | 28 |
| Buspirone Hcl | Buspirone Hcl | 115 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 24 |
| Trazodone Hcl | Trazodone Hcl | 97 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 24 |
| Ezetimibe | Ezetimibe | 94 | 16 |
| Jardiance | Empagliflozin | 94 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 25 |
| Potassium Chloride | Potassium Chloride | 86 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 12 |
| Alendronate Sodium | Alendronate Sodium | 77 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 75 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 16 |
| Ozempic | Semaglutide | 74 | 20 |
| Metformin Hcl Er | Metformin Hcl | 73 | 19 |
| Simvastatin | Simvastatin | 70 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 19 |
| Carvedilol | Carvedilol | 63 | 15 |
| Propranolol Hcl | Propranolol Hcl | 63 | 12 |
| Eliquis | Apixaban | 59 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 18 |
| Allopurinol | Allopurinol | 56 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Glimepiride | Glimepiride | 46 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | 15 |
| Meloxicam | Meloxicam | 42 | 12 |
| Atenolol | Atenolol | 41 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Cephalexin | Cephalexin | 19 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Kerendia | Finerenone | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Prednisone | Prednisone | 15 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Pindolol | Pindolol | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $343.98 · 16 records | Novo Nordisk Inc | ABRYSVO, Auvelity, COMIRNATY, Cologuard Collection Kit, INSPIRE, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error